However, a preclinical study showed that treatment of CDK4/6i and ET-resistant ER+/HER2− breast cancer models with everolimus restored sensitivity to CDK4/6i [73], suggesting that combining these therapies may be an option after progression on CDK4/6i71. Here, ESR1 is linked to breast cancer.